Editors view

Listed PE finds hope in secondaries

Steep discounts to NAV and a slowdown in exits have likely contributed to a rash of secondaries processes involving listed PE trusts.

Europe’s GP-led market is on a tear

An explosion of hefty – and, in some cases, repeat – continuation fund processes underscores the increasing maturation of Europe’s secondaries landscape.

Healthcare investing is at a vital juncture

Though the healthcare sector’s headline deal values may look healthy enough, policy upheavals in the US and ongoing fundraising pain may be weakening its underlying condition.

Traditional LPs and private wealth – the push for protections

LPs in drawdown funds are right to question how their exposure to investments will be affected by semi-liquid capital investing in the same deals.

LPs predict new manager formation will overtake GP M&A

Whether there are more or fewer emerging managers vis-à-vis consolidations will depend greatly on when sustainable levels of fundraising return.

Trump's One Big Beautiful Bill proves ugly for some

The US administration’s One Big Beautiful Bill Act is causing a raft of headaches for PE managers and LPs.

GPs must avoid ‘systemic risks’ in evergreens

A careful approach to selling and deploying semi-liquid products will help mitigate the most acute threats associated with raising ‘retail’ capital.

Private shares exchanges won't solve PE's liquidity woes

Exchange platforms must contend with a multitude of alternative liquidity paths for holders of private company stakes.

Anything but a CV?

Recent survey findings underscore the importance for GPs to explore multiple paths to liquidity before settling upon a continuation fund process.